A 48-year-old man with established rheumatoid arthritis has been on methotrexate 20 mg/week for 8 months but shows inadequate response with persistent synovitis in multiple joints and elevated inflammatory markers (CRP 8 mg/dL, ESR 55 mm/hr). He has no contraindications to biologic therapy. What is the drug of choice to add to his methotrexate regimen?

Explanation

## TNF Inhibitors as First-Line Biologic in RA **Key Point:** TNF-α inhibitors (particularly infliximab, etanercept, and adalimumab) are the preferred first-line biologic agents for MTX-inadequate responders in RA. ### Why TNF Inhibitors Are First-Line Biologics 1. **Strongest evidence base**: Longest clinical experience (>20 years), most robust RCT data, and largest real-world registries. 2. **Efficacy**: ACR50 response rates of 40–50% when combined with MTX; can achieve remission in 30–40% of patients. 3. **Rapid onset**: Clinical improvement within 2–4 weeks; radiological benefit evident by 12 weeks. 4. **Cost-effectiveness**: Most affordable biologic option in India; biosimilars now widely available. 5. **Guideline consensus**: ACR, EULAR, and Indian guidelines recommend TNF inhibitors as first-line biologic for MTX-inadequate responders. ### TNF Inhibitors in RA: Mechanism & Types **Mnemonic: IAEA** — Infliximab, Adalimumab, Etanercept, Anakinra (TNF inhibitors) | Agent | Type | MOA | Route | Frequency | |-------|------|-----|-------|----------| | **Infliximab** | Chimeric monoclonal Ab | Binds soluble & membrane TNF-α | IV | 3 mg/kg at weeks 0, 2, 6, then q8w | | **Etanercept** | TNF receptor fusion protein | Soluble TNF-R2 decoy | SC | 50 mg/week or 25 mg twice weekly | | **Adalimumab** | Fully human monoclonal Ab | Binds TNF-α | SC | 40 mg every 2 weeks | | **Anakinra** | IL-1 receptor antagonist | Blocks IL-1 signaling | SC | 100 mg daily (rarely used) | **High-Yield:** Infliximab is preferred in many guidelines because it requires concurrent MTX (which enhances efficacy and reduces anti-drug antibodies), has the longest clinical track record, and is most cost-effective in India. ### Rationale for Adding TNF Inhibitor to MTX ```mermaid flowchart TD A[MTX monotherapy inadequate response]:::outcome --> B{Add biologic agent}:::decision B -->|First-line| C[TNF inhibitor<br/>Infliximab/Etanercept/Adalimumab]:::action B -->|MTX contraindicated| D[Non-TNF biologic<br/>Abatacept/Rituximab]:::action C --> E[Combine with MTX]:::action D --> F[Monotherapy or with MTX]:::action E --> G[ACR50: 40-50%<br/>Remission: 30-40%]:::outcome F --> H[ACR50: 30-40%<br/>Remission: 20-30%]:::outcome ``` **Clinical Pearl:** TNF inhibitors MUST be combined with MTX (unless MTX contraindicated) to maximize efficacy, reduce immunogenicity (anti-drug antibodies), and improve long-term retention. ### Mandatory Screening Before TNF Inhibitor Initiation 1. **Tuberculosis**: Chest X-ray + tuberculin skin test (TST) or IGRA (QuantiFERON-Gold) - **Warning:** TNF inhibitors increase TB risk 4–25 fold; latent TB requires prophylaxis (isoniazid 6–9 months) before biologic start. 2. **Hepatitis B**: HBsAg, anti-HBc (risk of reactivation) 3. **HIV**: Anti-HIV serology (relative contraindication) 4. **CBC, LFTs, Creatinine**: Baseline assessment 5. **Pregnancy test**: Women of childbearing age ### Common Adverse Effects - **Infections**: Upper respiratory, UTI, pneumonia (most common) - **Tuberculosis**: Reactivation of latent TB (1–2% risk) - **Hepatotoxicity**: Elevated transaminases (usually mild) - **Hematologic**: Cytopenias (rare) - **Autoimmunity**: Drug-induced lupus, demyelinating disease (rare) - **Malignancy**: Slight increased risk of lymphoma (absolute risk remains low) **Warning:** TNF inhibitors are contraindicated in active infection, active TB, and demyelinating disease (MS, optic neuritis).